ISRCTN71212234 https://doi.org/10.1186/ISRCTN71212234

Chemotherapy with MOPP versus hybrid MOPP /EVAP in advanced Hodgkin's disease

Submission date	Recruitment status	[ ] Prospectively registered
01/07/2001	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
01/07/2001	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
21/01/2019	Cancer	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
H14

Study information

Scientific Title
Chemotherapy with MOPP versus hybrid MOPP/EVAP in advanced Hodgkin's disease

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Primary study design
Interventional

Study design
Randomised controlled trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Lymphoma (Hodgkin's)

Interventions
Patients are randomised to one of two chemotherapy regimens:
1. MOPP Regimen: Multi-drug chemotherapy with mustine, vincristine (Oncovin), procarbazine and prednisolone (MOPP) repeated every 4 weeks for a minimum of four courses.
2. MOPP/EVAP Regimen: Multi-drug chemotherapy with MOPP alternating every 2 weeks with etoposide, vinblastine, adriamycin and prednisolone (EVAP) for a minimum of eight courses of chemotherapy (ie four courses each of MOPP and EVAP).

Intervention Type
Drug

Phase
Not Applicable

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s)
Not provided at time of registration

Completion date
01/10/1993

Eligibility

Key inclusion criteria
1. Hodgkin's lymphoma stage IIB, III or IV
2. Staging to include adequate documentation of systemic symptoms, and Computed Tomography (CT) scan (except stage IV)
3. Local hisopathological review of diagnosis
4. No medical contraindications to treatment protocols

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/1989

Date of final enrolment
01/10/1993

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Cancer Research UK (CRUK) (UK)

ROR
https://ror.org/054225q67

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary